Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Palliative Care and Pain Management in Cancer
share announcement

Palliative Care and Pain Management in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 817

Special Issue Editors

Dr. María Fernández-Gonzáles

E-Mail Website
Guest Editor
Faculty of Health Sciences, University of Granada, 18071 Granada, Spain
Interests: quality of life; palliative care; cancer; rehabilitation
Dr. Moira O'Connor

E-Mail Website
Guest Editor
Discipline of Psychology, School of Population Health, Curtin Health Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA 6102, Australia
Interests: psycho-social aspects of cancer; palliative care

Special Issue Information

Dear Colleagues,

Pain is one of the most feared symptoms of cancer and is frequently under-evaluated and undertreated, despite the available control options. However, considerable progress has been made in the study, diagnosis, and treatment of cancer-related pain. Among patients with cancer, 58% experience pain: 33% report one type of pain, another 33% experience two types of pain, and the remaining 33% endure three or more types of pain. In patients with advanced cancer and palliative care settings, approximately two in three patients report suffering from pain. Pain significantly impacts patients’ daily lives, leading to a reduction in their quality of life (QoL). Moreover, there is a clear relationship between psychosocial variables and oncologic pain. Different approaches must be integrated into pain management strategies.

This Special Issue of Cancers therefore includes new research articles and timely reviews covering all aspects of pharmacological and non-pharmacological treatments for pain management in patients with advanced cancer.

Dr. María Fernández-Gonzáles
Dr. Moira O'Connor
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pain
  • quality of life
  • palliative care
  • non-pharmacological
  • pharmacological
  • cancer
  • metastasis
  • advanced cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1180 KiB  
Article
Evaluating Treatment Preferences and the Efficacy of Capsaicin 179 mg Patch vs. Pregabalin in a Randomized Trial for Postsurgical Neuropathic Pain in Breast Cancer: CAPTRANE
by Denis Dupoiron, Florent Bienfait, Valérie Seegers, François-Xavier Piloquet, Yves-Marie Pluchon, Marie Pechard, Karima Mezaib, Gisèle Chvetzoff, Jésus Diaz, Abesse Ahmeidi, Valérie Mauriès-Saffon, Nathalie Lebrec and Sabrina Jubier-Hamon
Cancers 2025, 17(2), 313; https://doi.org/10.3390/cancers17020313 - 19 Jan 2025
Viewed by 702
Abstract
Background/Objectives: CAPTRANE evaluated the efficacy and tolerability of high-concentration capsaicin patch (HCCP) vs. oral pregabalin for the treatment of postsurgical neuropathic pain (PSNP) following breast cancer surgery. The study was designed with the aim of demonstrating noninferiority of one HCCP against daily pregabalin. [...] Read more.
Background/Objectives: CAPTRANE evaluated the efficacy and tolerability of high-concentration capsaicin patch (HCCP) vs. oral pregabalin for the treatment of postsurgical neuropathic pain (PSNP) following breast cancer surgery. The study was designed with the aim of demonstrating noninferiority of one HCCP against daily pregabalin. Methods: This was a multicenter, randomized, parallel-arm, open-label study conducted across nine centers in France. The primary endpoint was a change from baseline in the Numeric Pain Rating Scale (NPRS) score after 2 months. Results: Recruitment challenges resulted in the randomization of 140 patients (versus 644 planned); the per-protocol population comprised 107 patients (HCCP: n = 65; pregabalin: n = 42). Baseline characteristics were similar between the two groups. In the per-protocol analysis, the mean (standard deviation) change versus baseline in NPRS score was −1.926 (2.554) with HCCP and −1.634 (2.498) with pregabalin. The prespecified analysis showed that HCCP was not inferior to pregabalin: the lower bound of the 90% confidence interval for the between-arm difference was −0.889 and the upper bound was +0.260 (i.e., below the predefined clinical threshold of +0.4). Patient-reported outcomes showed no statistically significant differences between treatments. The painful area size decreased significantly more with HCCP. Tolerability profiles differed, with HCCP mostly causing application-site reactions. While >50% of patients switched from pregabalin to HCCP, none switched from HCCP to pregabalin. Conclusions: This comparative study in PSNP post breast cancer surgery, evaluating a single treatment of HCCP, shows a noninferior reduction in pain intensity, a superior reduction in painful area size, and a patient preference for HCCP compared with pregabalin. Despite limitations, it contributes valuable initial data for PSNP management in breast cancer care. Full article
(This article belongs to the Special Issue Palliative Care and Pain Management in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop